OliX Pharmaceuticals, Inc. Logo

OliX Pharmaceuticals, Inc.

Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.

226950 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 고등동 608-3 -, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OliX Pharmaceuticals, Inc. is a clinical-stage biotechnology company that specializes in the development of novel therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric small interfering RNA (asiRNA) platform to discover and advance next-generation nucleic acid-based treatments. Its development pipeline is focused on addressing diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and metabolic disorders. Key programs in its pipeline target conditions such as hypertrophic scars, androgenetic alopecia (male-pattern baldness), age-related macular degeneration (AMD), and metabolic dysfunction-associated steatohepatitis (MASH). OliX aims to develop locally administrable therapies to improve safety and efficacy, positioning itself as an innovator in oligonucleotide therapeutics.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for OliX Pharmaceuticals, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.9 KB
2025-08-28 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-08-26 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.3 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 164.1 KB
2025-08-19 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 125.8 KB
2025-08-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB

Automate Your Workflow. Get a real-time feed of all OliX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OliX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896

Talk to a Data Expert

Have a question? We'll get back to you promptly.